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4) The Cost per Event-Free Patient model, based on the results
of the IDEAL Trial, compared cost effectiveness of the agents
included in that trial—high-dose (80 mg) atorvastatin vs. low-
dose (20–40 mg) simvastatin.
In addition, a budget impact analysis was performed to assist the
Committee in determining which group of agents best met 
the majority of the clinical needs of the DoD population at the
lowest cost to the MHS.
Implementation Strategy: On 23 October 2006, the Director,
TMA signed a decision paper accepting the DoD P&T Com-
mittee’s Antilipidemic-1 UF recommendations, with an imple-
mentation date of 1 February 2007. Accordingly, atorvastatin,
ﬂuvastatin immediate and extended release, pravastatin, simvas-
tatin, lovastatin immediate & extended release, lovastatin/niacin,
ezetimibe/simvastatin, niacin immediate and extended release,
and ezetimibe were maintained as formulary on the UF and rosu-
vastatin and atorvastatin/amlodipine were classiﬁed as non-for-
mulary under the UF.
Results: The DoD P&T Committee met its primary goal by pro-
viding a broad array of Antilipidemic-1 agents sufﬁcient to meet
the clinical needs for the majority of the DoD population. It also
met two of its primary objectives: 1) two agents were included
on the UF, in addition to simvastatin 80 mg, capable of achiev-
ing ≥45% LDL reduction (atorvastatin and simvastatin/ezetim-
ibe); 2) agents determined not to be cost-effective relative to
other agents in the class were designated as non-formulary on
the UF. Whether or not the DoD is successful in preserving sim-
vastatin market share will be closely monitored as this decision
is implemented.
Lessons Learned: Presentation of results from multiple cost effec-
tiveness models—which focus on different outcomes and use dif-
ferent methods, but are all based on an evidence-based review of
the clinical and pharmacoeconomic literature—increased the
Committee’s conﬁdence in making recommendations in this
class. The BIA, which incorporated factors not included in the
cost effectiveness models, further reﬁned the Committee’s under-
standing of the expected beneﬁts resulting from various formu-
lary scenarios.
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Problem or Issue Addressed: Excessive use of a high cost non-
formulary drug.
Goal: To evaluate the use of Levalbuterol in a teaching hospital
and to determine need for inclusion (if any) on the hospital 
formulary.
Outcomes items used in the decision: Levalbuterol is FDA-
approved for the treatment or prevention of acute bronchospasm
in adults, adolescents, and children aged 6 or older with
reversible obstructive airway disease. Our institution recently
realized a signiﬁcant increase in the purchasing of this agent,
which prompted an intensive evaluation of the prescribing habits
surrounding levalbuterol. The purpose of our study was to iden-
tify the indications for levalbuterol use, evaluate the appro-
priateness of dosing, determine contraindications to alternate
therapies, and recognize adverse events, if any, associated with
levalbuterol use.
Implementation Strategy: This evaluation was a criteria-based,
retrospective evaluation of all patients for whom levalbuterol
was prescribed over an 18 month period. All patients were iden-
tiﬁed from computerized pharmacy records. Patient therapy was
evaluated via physician progress notes, laboratory reports, and
physician orders. Purchase data was determined via the phar-
macy’s computerized medication inventory management system.
Results: The majority of levalbuterol use was in pediatric
patients (27%), followed by cardiac surgery patients (17%) and
internal medicine service patients (14%). Indications of short-
ness of breath or respiratory distress associated with various
disease states and medical procedures comprised 38% of leval-
buterol use. 35% of use was in COPD (20%) and asthma (15%)
combined. The majority of patients received levalbuterol for <3
days at a dosing frequency of less than every 6 hours. 80% of
patients received albuterol therapy prior to levalbuterol admin-
istration. No adverse events related to levalbuterol use were
reported.
Conclusions/Lessons Learned: Our study reveals that patients
are prescribed levalbuterol for a variety of indications, most of
which are non-FDA approved uses. Patients at high risk for
cardiac side effects, including pediatric and cardiac surgery
patients, are likely to receive levalbuterol. Prescribers typically
utilize levalbuterol after patients failed to improve on or experi-
enced side effects to albuterol. Dosing frequency exceeded
approved labeling and established guidelines in most cases.
Determined there may be a need to include levalbuterol on the
hospital formulary restricted to pediatric patients meeting certain
speciﬁc criteria.
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Problem or Issue Addressed: Increasing costs of Antibiotics
Goals: To determine the reasons for increased costs of antibiotics
at a rehabilitation hospital, and to determine whether interven-
tions were necessary to reduce costs and improve outcomes.
Outcomes items used in the decision: a) organism susceptibility
per cultures when compared to empiric antibiotics selected; b)
proportion of empiric antibiotics subsequently determined to be
resistant; c) incidence of intravenous medications when patient
was receiving oral medications; d) duration of antibiotic therapy
when patient was asymptomatic (and compared to recom-
mended duration of therapy); and e) appropriate dose and inter-
val based on patient’s renal function.
Implementation Strategy: Random sampling of patients receiv-
ing antibiotics used in the previous 12 months.
Results: 1. More cost-effective medication were available empir-
ically in the treatment of UTI and Cellulitus. 2. Selection of resis-
tant antibiotics occurred infrequently, but when encountered, the
change in antibiotics was delayed at times. 3. Some asympto-
matic patients who were receiving all other medications oral
could have been switched from IV to PO antibiotics. 4. Some
excess duration because of antibiotic use at prior facility. 5. Dose
and interval appropriate with some adjustments require for renal
function, readily accepted by physicians.
Conclusions/Lessons Learned: Antibiotic selection needs some
intervention. Three part program will be implemented: 1. Some
restrictions on availability of ordering IV antibiotics without ID
consult. 2. Physician education as to proper dose, interval, and
frequency. 3. A pharmacy-run infectious disease service to guide
empiric selection and ensure quick review of cultures.
